Travere Therapeutics Reports Third Quarter 2022 Financial Results
27 oct. 2022 16h01 HE
|
Travere Therapeutics, Inc.
EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023 New PDUFA target action date for...